Cited by 487Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsMedical Imaging Techniques and Applications

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer’s disease

Open access
Mosconi, Lisa, Mistur, Rachel, Switalski, Remigiusz, Tsui, Wai Hon, Glodzik, Lidia, Li, Yi, Pirraglia, Elizabeth, De Santi, Susan +3 more·2009·European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Purpose We report the first clinicopathological series of longitudinal FDG-PET scans in post-mortem (PM) verified cognitively normal elderly (NL) followed to the onset of Alzheimer's-type dementia (DAT), and in patients with mild DAT with progressive cognitive deterioration.Methods Four NL subjects and three patients with mild DAT received longitudinal clinical, neuropsychological and dynamic FDG-PET examinations with arterial input functions. NL subjects were followed for 13 +/- 5 years, received FDG-PET examinations over 7 +/- 2 years, and autopsy 6 +/- 3 years after the last FDG-PET. Two NL declined to mild cognitive impairment (MCI), and two developed probable DAT before death. DAT patients were followed for 9 +/- 3 years, received FDG-PET examinations over 3 +/- 2 years, and autopsy 7 +/- 1 years after the last FDG-PET. Two DAT patients progressed to moderate-to-severe dementia and one developed vascular dementia.Results The two NL subjects who declined to DAT received a PM diagnosis of definite AD. Their FDG-PET scans indicated a progression of deficits in the cerebral metabolic rate for glucose (CMRglc) from the hippocampus to the parietotemporal and posterior cingulate cortices. One DAT patient showed AD with diffuse Lewy body disease (LBD) at PM, and her last in vivo PET was indicative of possible LBD for the presence of occipital as well as parietotemporal hypometabolism.Conclusion Progressive CMRglc reductions on FDG-PET occur years in advance of clinical DAT symptoms in patients with pathologically verified disease. The FDG-PET profiles in life were consistent with the PM diagnosis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-008-1039-z

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain.

    “However, oxidative stress, mitochondrial dysfunction, and glucose hypometabolism have been well documented in MCI and AD brain [8,53,74,75,76].”

    From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [76]

    The Discussion (page not provided) reports reduced brain glucose metabolism in people progressing to MCI and Alzheimer’s dementia. The paper does not document the sentence’s other attributed findings, oxidative stress or mitochondrial dysfunction. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Patients with mild cognitive impairment and Alzheimer's disease exhibit deficits in brain energy metabolism years before symptom onset.

    “Numerous studies show that patients with mild cognitive impairment (MCI) and AD exhibit deficits in brain energy metabolism years before disease symptom onset [8][9][10][11] .”
  • Regional reductions in brain glucose utilization occur with aging and to a greater extent in MCI and AD.

    “Regional reductions in brain glucose utilization occur with aging and to a greater extent in MCI and AD [185-193].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [22]George AE de Leon MJ Kalnin A Rosner L Goodgold A Chase N Leukoencephalopathy in normal and pathologic aging: 2. MRI and brain lucencies AJNR Am J Neuroradiol 1986 7 567 70 3088934 PMC8334676

Cited by

Sorted by citations

Authors
Mosconi, L., Mistur, R., Switalski, R., Tsui, W. H., Glodzik, L., Li, Y., Pirraglia, E., De Santi, S., Reisberg, B., Wisniewski, T., & de Leon, M. J.
Affiliations
  • New York University (US)
  • Nathan Kline Institute for Psychiatric Research (US)
Corresponding author
Mosconi, Lisa
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2009-01-14
Volume
36
Issue
5
Pages
811-822
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2043768383
Cited by
487
References
40
Citations by year
2026: 23 · 2025: 29 · 2024: 27 · 2023: 23 · 2022: 36 · 2021: 29 · 2020: 25 · 2019: 38 · 2018: 22 · 2017: 30 · 2016: 24 · 2015: 27 · 2014: 34 · 2013: 30 · 2012: 30
FWCI
18.29
Type
journal article
Language
en
Open access
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute on Aging (AG022374, AG03051, R01AG003051, R01AG022374, AG 12101, R01AG012101, P30AG008051, AG 08051, R01AG013616, AG 13616)
  • National Center for Research Resources (M01RR0096, M01RR000096)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Keywords
Alzheimer's disease, FDG-PET, brain glucose metabolism, cerebral metabolic rate of glucose, mild cognitive impairment, dementia onset, postmortem neuropathology, posterior cingulate cortex, Lewy body disease, vascular dementia, arterial input function
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Autopsy, Brain, Cognition Disorders, Female, Glucose, Hippocampus, Humans, Male, Dementia, Vascular, Fluorodeoxyglucose F18, Lewy Body Disease, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review